Literature DB >> 15285756

Antitumor effect of simultaneous transfer of interleukin-12 and interleukin-18 genes and its mechanism in a mouse bladder cancer model.

Satoko Hikosaka1, Isao Hara, Hideaki Miyake, Shoji Hara, Sadao Kamidono.   

Abstract

BACKGROUND: The objectives of this study were to evaluate the antitumor effects of the simultaneous introduction of interleukin 12 (IL-12) and IL-18 genes into a mouse bladder cancer cell line (MBT2). We intended to compare these with those of either gene alone and to investigate the mechanism of the effects induced by the transfer of IL-12 and/or IL-18 genes in this model system.
METHODS: We transfected the IL-12 and/or IL-18 genes into MBT2 cells by the liposome-mediated gene transfer method. We confirmed the secretion of IL-12 and/or IL-18 by enzyme-linked immunosorbent assay. Parental (MBT2/P), IL-12-transfected (MBT2/IL-12), IL-18-transfected (MBT2/IL-18) or both IL-12- and IL-18-transfected (MBT2/Both) cells were subcutaneously or intravenously injected into syngeneic C3H mice. To analyze the mechanism of tumor rejection, these clones were subcutaneously injected into naive nude mice and those depleted with natural killer (NK) cells by antibody.
RESULTS: MBT2/IL-12, MBT2/IL-18 and MBT2/Both were completely rejected when they were injected subcutaneously or intravenously into syngeneic mice. However, MBT2/IL-12, but not MBT2/IL-18, could grow in nude mice. Moreover, the antitumor effect of MBT2/IL-18 was partially abrogated when injected into nude mice of which NK cells were depleted by antibody treatment. MBT2/Both was completely rejected in both nude mice with and without NK cells.
CONCLUSION: The results of the present study indicate that T cells and NK cells seem to play important roles in the antitumor effects by the secretion of IL-12 and IL-18, respectively, and MBT2/Both possesses both mechanisms.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15285756     DOI: 10.1111/j.1442-2042.2004.00855.x

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  7 in total

Review 1.  Recent advances in intravesical drug/gene delivery.

Authors:  Pradeep Tyagi; Pao-Chu Wu; Michael Chancellor; Naoki Yoshimura; Leaf Huang
Journal:  Mol Pharm       Date:  2006 Jul-Aug       Impact factor: 4.939

2.  Expression and significance of intratumoral interleukin-12 and interleukin-18 in human gastric carcinoma.

Authors:  Zheng-Bao Ye; Tao Ma; Hao Li; Xiao-Long Jin; Hai-Min Xu
Journal:  World J Gastroenterol       Date:  2007-03-21       Impact factor: 5.742

3.  Innate immunity: a cutaneous perspective.

Authors:  Heidi Goodarzi; Janet Trowbridge; Richard L Gallo
Journal:  Clin Rev Allergy Immunol       Date:  2007-10       Impact factor: 10.817

4.  IL-18 inhibits growth of murine orthotopic prostate carcinomas via both adaptive and innate immune mechanisms.

Authors:  Brian Wan-Chi Tse; Pamela Joan Russell; Matthias Lochner; Irmgard Förster; Carl Andrew Power
Journal:  PLoS One       Date:  2011-09-15       Impact factor: 3.240

5.  Tumor and microenvironment modification during progression of murine orthotopic bladder cancer.

Authors:  Sin Mun Tham; Kee Hui Ng; Sim Hwee Pook; Kesavan Esuvaranathan; Ratha Mahendran
Journal:  Clin Dev Immunol       Date:  2011-10-13

6.  Enhanced Control of Bladder-Associated Tumors Using Shrimp Anti-Lipopolysaccharide Factor (SALF) Antimicrobial Peptide as a Cancer Vaccine Adjuvant in Mice.

Authors:  Han-Ning Huang; Venugopal Rajanbabu; Chieh-Yu Pan; Yi-Lin Chan; Jyh-Yih Chen; Chang-Jer Wu
Journal:  Mar Drugs       Date:  2015-05-21       Impact factor: 5.118

7.  Enhancement of phagocytosis and cytotoxicity in macrophages by tumor-derived IL-18 stimulation.

Authors:  Xu Henan; Naoka Toyota; Xing Yanjiang; Yuuki Fujita; Huang Zhijun; Maki Touma; Wu Qiong; Kenkichi Sugimoto
Journal:  BMB Rep       Date:  2014-05       Impact factor: 4.778

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.